Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
0.6603
-0.0307 (-4.44%)
At close: Mar 26, 2026, 4:00 PM EDT
0.6603
0.00 (0.00%)
Pre-market: Mar 27, 2026, 7:32 AM EDT
Biodexa Pharmaceuticals Revenue
Biodexa Pharmaceuticals had revenue of 27.00K GBP in the half year ending June 30, 2025, a decrease of -90.94%.
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
4.09M USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 381.00K | -318.00K | -45.49% |
| Dec 31, 2022 | 699.00K | 654.62K | 1,475.10% |
| Feb 28, 2022 | 44.38K | -533.62K | -92.32% |
| Dec 31, 2021 | 578.00K | -4.02M | -87.43% |
| Feb 28, 2021 | 4.60M | 4.25M | 1,240.44% |
| Dec 31, 2020 | 343.00K | -331.00K | -49.11% |
| Dec 31, 2019 | 674.00K | -1.26M | -65.22% |
| Dec 31, 2018 | 1.94M | 949.00K | 95.96% |
| Dec 31, 2017 | 989.00K | -334.00K | -25.25% |
| Dec 31, 2016 | 1.32M | -52.00K | -3.78% |
| Dec 31, 2015 | 1.38M | 1.22M | 775.80% |
| Dec 31, 2014 | 157.00K | 10.00K | 6.80% |
| Dec 31, 2013 | 147.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBDRX News
- 3 days ago - Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group - GlobeNewsWire
- 8 days ago - ADR Ratio Change - GlobeNewsWire
- 17 days ago - Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients - GlobeNewsWire
- 5 weeks ago - Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer - Accesswire
- 7 weeks ago - Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST - GlobeNewsWire
- 2 months ago - Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary - GlobeNewsWire
- 3 months ago - Biodexa Announces Pricing of $10 Million Public Offering - GlobeNewsWire
- 4 months ago - Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP - GlobeNewsWire